share_log

HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $64

Benzinga ·  Nov 28, 2023 09:33

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the price target from $52 to $64.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment